Neurotrack is a digital cognitive function screening tool designed for healthcare providers. It helps identify risks related to mild cognitive impairment, dementia, and Alzheimerβs disease. The official website emphasizes that it is a clinically validated, FDA-registered product suitable for primary care, virtual care, and home care workflows. Its goal is to standardize cognitive testing, reduce missed diagnoses, and improve the efficiency of early intervention.
The product can establish a cognitive baseline in about 3 minutes, with additional tests unlocked when needed. Results are scored instantly and aligned with DSM-5, while functional questionnaires are incorporated to help care teams make triage, diagnosis, and referral decisions. Its care plan module generates next-step recommendations based on the severity of cognitive impairment and key EHR data, and can connect patients and caregivers with local resources. The website also mentions support for remote screening, real-time analytics, and population-level screening, making it suitable for value-based care, HEDIS, CMS, and annual wellness visit scenarios.
Neurotrack claims it can run on any device and integrate with all EHR systems, but it does not disclose specific vendors, integration methods, or API documentation. On security and compliance, the website explicitly mentions SOC 2, HIPAA compliance, and FDA registration, which are important advantages for healthcare procurement. Based on the description, the deployment model appears to be cloud-based SaaS and supports virtual visits and home care, but no self-hosting option is mentioned.
The official website does not publicly list plans, pricing, billing metrics, a free version, or trial information in its main content, and only provides a demo request option. Buyers will therefore need to confirm with sales whether pricing is based on institution, number of clinicians, screening volume, or project scope, and whether implementation, training, and EHR integration are charged separately.
Its strengths lie in its focused approach to cognitive screening, relatively complete clinical evidence and compliance positioning, and strong fit with healthcare workflows. It also claims availability to 15,000+ clinicians and savings of more than 10 minutes per patient. Its weaknesses include limited commercial transparency and a lack of information on third-party integrations, permission management, APIs, and local support in China. It is better suited to U.S. healthcare systems, payers, primary care groups, home care providers, and research collaboration projects.
The official website does not provide information on China access, RMB payment, a Chinese-language interface, or local compliance, so its practical availability is unknown. Chinese healthcare institutions considering procurement would also need to evaluate network connectivity, cross-border data transfer, patient privacy, and local medical device regulatory requirements. Alternatives may include traditional Mini-Cog, MMSE, MoCA, and SLUMS tests, as well as local hospital IT systems or digital cognitive assessment vendors.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on neurotrack.com official site.
neurotrack.com is an United States SaaS Tools provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach neurotrack.com directly.